Goldman Sachs Upgrades Alexion Pharmaceuticals (ALXN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
FBR Capital Upgrades Alexion Pharmaceuticals (ALXN) to Market Perform
October 28, 2016 6:35 AM EDTFBR Capital upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Underperform to Market Perform with a price target of $130.00.
Analyst Christopher James commented, "Yesterday, Alexion reported its financial results for 3Q16. Total revenues came in at $799 million, well above our and the consensus estimates of $743 million and $787 million,... More
Alexion Pharma (ALXN) Tops Q3 EPS by 6c; Guides Relativity In-Line
October 27, 2016 6:35 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.23, $0.06 better than the analyst estimate of $1.17. Revenue for the quarter came in at $799 million versus the consensus estimate of $786.86 million.
GUIDANCE:
Alexion Pharma sees FY2016 EPS at upper end of $4.50-$4.65, versus... More
Alexion Pharma (ALXN) Commences Two ALXN1210 Phase 3s
October 27, 2016 6:32 AM EDTAlexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement. The first trial is a Phase 3 open-label, multinational, active-controlled study of ALXN1210 compared to eculizumab (Soliris®) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion has also accelerated the initiation of a registration trial of ALXN1210 in patients with atypical hemolytic uremic syndrome (aHUS). This second trial is a Phase 3, open-label, single arm, multinational trial to evaluate the safety and efficacy of ALXN1210 in complement inhibitor... More
